These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2798233)

  • 21. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of prolactin on rat dorsolateral prostate and R3327 prostatic tumor sublines.
    Johnson MP; Thompson SA; Lubaroff DM
    J Urol; 1985 Jun; 133(6):1112-20. PubMed ID: 4039764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI; Ikezoe T; Carey M; Holden S; Tomoyasu S; Koeffler HP
    Cancer Res; 2000 Oct; 60(19):5494-8. PubMed ID: 11034093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model.
    Pilat MJ; Lehr JE; Quigley MM; Pienta KJ
    Oncol Rep; 1998; 5(4):889-92. PubMed ID: 9625839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.
    Pienta KJ; Nguyen NM; Lehr JE
    Cancer Res; 1993 Jan; 53(2):224-6. PubMed ID: 7678070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
    Dijkman GA; Van Moorselaar RJ; Van Ginckel R; Van Stratum P; Wouters L; Debruyne FM; Schalken JA; de Coster R
    J Urol; 1994 Jan; 151(1):217-22. PubMed ID: 8254818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089.
    Perez-Stable CM; Schwartz GG; Farinas A; Finegold M; Binderup L; Howard GA; Roos BA
    Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):555-63. PubMed ID: 12050097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histology and ultrastructure of the R-3327 C-F transplantable prostate tumor of Cophenhagen-Fisher rats.
    Seman G; Myers B; Bowen JM; Dmochowski L
    Invest Urol; 1978 Nov; 16(3):231-6. PubMed ID: 711418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epithelial origin of a stromal cell population in adenocarcinoma of the rat prostate.
    Beckman WC; Camps JL; Weissman RM; Kaufman SL; Sanofsky SJ; Reddick RL; Siegal GP
    Am J Pathol; 1987 Sep; 128(3):555-65. PubMed ID: 2443013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
    Oades GM; Dredge K; Kirby RS; Colston KW
    BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
    Lokeshwar BL; Hurkadli KS; Sheth AR; Block NL
    Cancer Res; 1993 Oct; 53(20):4855-9. PubMed ID: 8402673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth-inhibitory action of melatonin and thiazolidinedione derivative CGP 52608 on murine 16/C breast cancer cells.
    Winczyk K; Lawnicka H; Pawlikowski M; Kunert-Radek J; Karasek M
    Neuro Endocrinol Lett; 2006 Jun; 27(3):351-4. PubMed ID: 16816834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone.
    Szepeshazi K; Korkut E; Schally AV
    Am J Pathol; 1991 May; 138(5):1273-7. PubMed ID: 1827237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
    Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Observations with an S-adenosylmethionine decarboxylase inhibitor in rats with prostatic adenocarcinoma.
    Seiler N; Delcros JG; Cipolla B; Chamaillard L; Havouis R; Quemener V; Moulinoux JP
    Arzneimittelforschung; 1996 Mar; 46(3):311-5. PubMed ID: 8901156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats.
    Van Ginckel R; De Coster R; Wouters W; Vanherck W; van der Veer R; Goeminne N; Jagers E; Van Cauteren H; Wouters L; Distelmans W
    Prostate; 1990; 16(4):313-23. PubMed ID: 2371176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
    Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
    Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen treatment combined with castration inhibits tumor growth more effectively than castration alone in the Dunning R3327 rat prostatic adenocarcinoma.
    Landström M; Bergh A; Tomic R; Damber JE
    Prostate; 1990; 17(1):57-68. PubMed ID: 1696714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.
    Williams SA; Merchant RF; Garrett-Mayer E; Isaacs JT; Buckley JT; Denmeade SR
    J Natl Cancer Inst; 2007 Mar; 99(5):376-85. PubMed ID: 17341729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.